Oncology & Cancer

Interferon not beneficial for most stage III melanoma

Final results for the Sunbelt Melanoma Trial, published online this month in the Journal of Clinical Oncology, show that thanks to current diagnostic techniques, most stage III melanoma patients do not benefit from treatment ...

Oncology & Cancer

Histologic regression tied to lower odds of SLN positivity

(HealthDay)—For patients with primary melanoma, the risk of sentinel lymph node (SLN) positivity is significantly lower for those with histologic regression, according to a review published online Sept. 2 in JAMA Dermatology.

Oncology & Cancer

Presurgical SPECT/CT shows more cancer than current standard

Startling data from an international multi-center trial provide growing evidence that sentinel node imaging is more effectively accomplished with hybrid functional imaging with single photon emission computed tomography and ...

page 3 from 8